Long-Term Safety of Drug-Eluting and Bare-Metal Stents Evidence From a Comprehensive Network Meta-Analysis

T Palmerini, U Benedetto, G Biondi-Zoccai, D Riva, L Bacchi-Reggiani, PC (Pieter) Smits, GJ Vlachojannis, LO Jensen, EH Christiansen, K Berencsi, Marco Valgimigli, C Orlandi, M Petrou, C Rapezzi, GW Stone

Research output: Contribution to journalArticleAcademicpeer-review

333 Citations (Scopus)

Abstract

BACKGROUND Previous meta-analyses have investigated the relative safety and efficacy profiles of different types of drug-eluting stents (DES) and bare-metal stents (BMS); however, most prior trials in these meta-analyses reported follow-up to only 1 year, and as such, the relative long-term safety and efficacy of these devices are unknown. Many recent studies have now reported extended follow-up data. OBJECTIVES This study sought to investigate the long-term safety and efficacy of durable polymer-based DES, bioabsorbable polymer-based biolimus-eluting stents (BES), and BMS by means of network meta-analysis. METHODS Randomized controlled trials comparing DES to each other or to BMS were searched through MEDLINE, EMBASE, and Cochrane databases and proceedings of international meetings. Information on study design, inclusion and exclusion criteria, sample characteristics, and clinical outcomes was extracted. RESULTS Fifty-one trials that included a total of 52,158 randomized patients with follow-up duration >= 3 years were analyzed. At a median follow-up of 3.8 years, cobalt-chromium everolimus-eluting stents (EES) were associated with lower rates of mortality, definite stent thrombosis (ST), and myocardial infarction than BMS, paclitaxel-eluting stents (PES), and sirolimus-eluting stents (SES) and less ST than BES. Phosphorylcholine-based zotarolimus-eluting stents had lower rates of definite ST than SES and lower rates of myocardial infarction than BMS and PES. The late rates of target-vessel revascularization were reduced with all DES compared with BMS, with cobalt-chromium EES, platinum chromium-EES, SES, and BES also having lower target-vessel revascularization rates than PES. CONCLUSIONS After a median follow-up of 3.8 years, all DES demonstrated superior efficacy compared with BMS. Among DES, second-generation devices have substantially improved long-term safety and efficacy outcomes compared with first-generation devices. (C) 2015 by the American College of Cardiology Foundation.
Original languageUndefined/Unknown
Pages (from-to)2496-2507
Number of pages12
JournalJournal of the American College of Cardiology
Volume65
Issue number23
DOIs
Publication statusPublished - 2015

Cite this